29 January 2026
29 January 2026
The trial plans to enrol around 700 adults with CIC, with the primary endpoint assessing patient-reported constipation outcomes.
The FDA has authorised up to 15 clinical sites to take part in the study.
The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027.
QT Imaging data will be enabled for clinical interpretation by incorporating Olea Medical’s analytics technologies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
